MULTIHANCE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Multihance, and what generic alternatives are available?
Multihance is a drug marketed by Bracco and is included in two NDAs.
The generic ingredient in MULTIHANCE is gadobenate dimeglumine. One supplier is listed for this compound. Additional details are available on the gadobenate dimeglumine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MULTIHANCE?
- What are the global sales for MULTIHANCE?
- What is Average Wholesale Price for MULTIHANCE?
Summary for MULTIHANCE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 9 |
| Patent Applications: | 173 |
| Drug Prices: | Drug price information for MULTIHANCE |
| What excipients (inactive ingredients) are in MULTIHANCE? | MULTIHANCE excipients list |
| DailyMed Link: | MULTIHANCE at DailyMed |
Pharmacology for MULTIHANCE
| Drug Class | Gadolinium-based Contrast Agent |
| Mechanism of Action | Magnetic Resonance Contrast Activity |
US Patents and Regulatory Information for MULTIHANCE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bracco | MULTIHANCE | gadobenate dimeglumine | INJECTABLE;INTRAVENOUS | 021357-001 | Nov 23, 2004 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bracco | MULTIHANCE | gadobenate dimeglumine | INJECTABLE;INTRAVENOUS | 021357-004 | Nov 23, 2004 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bracco | MULTIHANCE | gadobenate dimeglumine | INJECTABLE;INTRAVENOUS | 021357-002 | Nov 23, 2004 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MULTIHANCE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bracco | MULTIHANCE | gadobenate dimeglumine | INJECTABLE;INTRAVENOUS | 021357-001 | Nov 23, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| Bracco | MULTIHANCE | gadobenate dimeglumine | INJECTABLE;INTRAVENOUS | 021357-004 | Nov 23, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| Bracco | MULTIHANCE | gadobenate dimeglumine | INJECTABLE;INTRAVENOUS | 021357-003 | Nov 23, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MULTIHANCE
See the table below for patents covering MULTIHANCE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Germany | 440606 | ⤷ Sign Up | |
| Ireland | 67551 | Macrocyclic chelating agents and chelates thereof | ⤷ Sign Up |
| Germany | 3853415 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MULTIHANCE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0230893 | SPC/GB97/081 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: GADOBENATE DIMEGLUMINE; REGISTERED: UK 06099/0006 19970722 |
| 0230893 | C980024 | Netherlands | ⤷ Sign Up | PRODUCT NAME: GADOBEENZUUR,DESGEWENST IN DE VORM VAN EEN ZOUT MET EEN ALKA- LIMETAAL, AARDALKALIMETAAL, OF BASISCH GEPROTONEERD AMINOZUUR OF VAN EEN ALKYLAMMONIUM-, ALKANOLAMMONIUM- OF POLYHYDROXYAL- KYLAMMONIUMZOUT, IN HET BIJZONDER DIMEGLUMINI GADOBENAS; NAT. REGISTRATION NO/DATE: RVG 22324 19980706; FIRST REGISTRATION: GB PL 06099/0006 19970722 |
| 0230893 | 99C0013 | Belgium | ⤷ Sign Up | PRODUCT NAME: GADOBENAATDIMEGLUMINE; NAT. REGISTRATION NO/DATE: 3503 IE 48 F 12 19990201; FIRST REGISTRATION: GB PL 06099/0006 19970722 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
